How does interferon work? Does it even matter?

Cancer

Volumn 95, Issue 5, 2002, Pages 947-949

  Sondak, Vernon K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DOSE RESPONSE; DRUG ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; MELANOMA; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON ALFA-2B; MELANOMA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 0036720604     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10779     Document Type: Short Survey

References (21)

1. Interferon alfa therapy for malignant melanoma: A systemic review of randomized controlled trials
2. Pros and cons of adjuvant interferon in the treatment of melanoma
3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
4. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190
5. Postsurgical adjuvant therapy of melanoma: Evaluation of a 3-year randomized trial with recombinant interferon-α after 3 and 5 years of follow-up
6. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
7. Adjuvant interferon alfa-2a treatment in resected primary Stage II cutaneous melanoma
8. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801
9. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group Phase II trial E2696
10. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons
11. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma
12. EORTC 18871 adjuvant trial in high risk melanoma patients: IFNα vs IFNγ vs Iscador vs observation
13. Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer
14. The determination of an immunologically active dose of interferon-gamma in patients with melanoma
15. Immunomodulatory effects of high-and low-dose IFNa2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of Intergroup adjuvant trial E1690
16. Results of adjuvant interferon study in WHO melanoma programme
17. Angiogenesis and cancer metastasis
18. The Sunbelt Melanoma Trial
19. Adjuvant interferon alpha 2b in high risk melanoma - The Scottish study
20. Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKC-CCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma
21. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b